| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ethics Committees, Research | 14 | 2023 | 194 | 4.460 |
Why?
|
| Clinical Trials as Topic | 24 | 2023 | 7914 | 2.630 |
Why?
|
| Biomedical Research | 20 | 2022 | 3309 | 2.560 |
Why?
|
| Information Dissemination | 12 | 2023 | 1099 | 2.130 |
Why?
|
| Research Subjects | 7 | 2020 | 239 | 2.070 |
Why?
|
| T-Lymphocytes | 66 | 2006 | 10183 | 1.920 |
Why?
|
| Ethics, Research | 7 | 2022 | 191 | 1.670 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 27 | 1994 | 906 | 1.530 |
Why?
|
| Authorship | 3 | 2019 | 271 | 1.500 |
Why?
|
| Informed Consent | 7 | 2023 | 995 | 1.470 |
Why?
|
| Patient Selection | 8 | 2021 | 4216 | 1.390 |
Why?
|
| Patient Participation | 4 | 2023 | 1457 | 1.360 |
Why?
|
| Tacrolimus | 32 | 2003 | 743 | 1.310 |
Why?
|
| Lymphocyte Activation | 44 | 2003 | 5524 | 1.280 |
Why?
|
| Confidentiality | 7 | 2024 | 612 | 1.260 |
Why?
|
| Polyenes | 21 | 1996 | 69 | 1.120 |
Why?
|
| Cyclosporine | 21 | 2003 | 788 | 1.050 |
Why?
|
| Research Design | 9 | 2023 | 5984 | 1.040 |
Why?
|
| Human Experimentation | 2 | 2017 | 127 | 1.030 |
Why?
|
| Receptors, Immunologic | 20 | 1994 | 1423 | 1.020 |
Why?
|
| Ethics Committees | 1 | 2023 | 54 | 0.930 |
Why?
|
| Delphi Technique | 2 | 2023 | 779 | 0.910 |
Why?
|
| Clinical Trials Data Monitoring Committees | 1 | 2023 | 25 | 0.880 |
Why?
|
| Disabled Persons | 2 | 2022 | 1212 | 0.870 |
Why?
|
| Behavioral Research | 1 | 2022 | 54 | 0.830 |
Why?
|
| Ethical Review | 2 | 2019 | 26 | 0.830 |
Why?
|
| Clinical Protocols | 2 | 2020 | 1461 | 0.820 |
Why?
|
| Phosphoprotein Phosphatases | 15 | 1996 | 338 | 0.780 |
Why?
|
| Acupuncture Therapy | 2 | 2022 | 464 | 0.770 |
Why?
|
| Civil Rights | 1 | 2022 | 132 | 0.760 |
Why?
|
| Calcineurin | 17 | 2003 | 226 | 0.740 |
Why?
|
| Achievement | 1 | 2022 | 291 | 0.740 |
Why?
|
| Immunosuppressive Agents | 22 | 2005 | 4153 | 0.730 |
Why?
|
| Privacy | 2 | 2024 | 238 | 0.710 |
Why?
|
| Compensation and Redress | 1 | 2019 | 71 | 0.690 |
Why?
|
| Journalism, Medical | 1 | 2020 | 74 | 0.690 |
Why?
|
| Calmodulin-Binding Proteins | 14 | 1996 | 250 | 0.680 |
Why?
|
| Disclosure | 3 | 2023 | 736 | 0.680 |
Why?
|
| Triage | 2 | 2023 | 977 | 0.680 |
Why?
|
| Antigens, CD | 22 | 2001 | 4026 | 0.660 |
Why?
|
| Truth Disclosure | 1 | 2023 | 436 | 0.660 |
Why?
|
| Pandemics | 7 | 2024 | 8385 | 0.650 |
Why?
|
| Government Regulation | 4 | 2018 | 522 | 0.650 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2020 | 780 | 0.640 |
Why?
|
| Dental Care | 1 | 2021 | 262 | 0.640 |
Why?
|
| Actins | 5 | 2006 | 2121 | 0.640 |
Why?
|
| Editorial Policies | 2 | 2020 | 451 | 0.640 |
Why?
|
| Motivation | 5 | 2020 | 1971 | 0.620 |
Why?
|
| Ecosystem | 1 | 2022 | 474 | 0.620 |
Why?
|
| Clinical Competence | 3 | 2022 | 4687 | 0.610 |
Why?
|
| Social Values | 1 | 2018 | 224 | 0.610 |
Why?
|
| Membrane Glycoproteins | 16 | 1999 | 3771 | 0.610 |
Why?
|
| Attitude | 1 | 2022 | 776 | 0.610 |
Why?
|
| Universal Precautions | 1 | 2017 | 34 | 0.610 |
Why?
|
| Humans | 187 | 2024 | 744366 | 0.580 |
Why?
|
| Jurkat Cells | 13 | 2006 | 743 | 0.570 |
Why?
|
| Phlebotomy | 1 | 2017 | 141 | 0.560 |
Why?
|
| Morals | 4 | 2022 | 285 | 0.560 |
Why?
|
| Antigens, Surface | 13 | 1991 | 1663 | 0.550 |
Why?
|
| Receptors, Antigen, T-Cell | 20 | 2001 | 2540 | 0.530 |
Why?
|
| Databases, Factual | 4 | 2023 | 7730 | 0.510 |
Why?
|
| Consent Forms | 3 | 2021 | 53 | 0.510 |
Why?
|
| Interleukin-2 | 28 | 2006 | 1904 | 0.500 |
Why?
|
| Registries | 4 | 2023 | 8091 | 0.490 |
Why?
|
| Facility Regulation and Control | 1 | 2014 | 24 | 0.490 |
Why?
|
| Duty to Warn | 1 | 2014 | 30 | 0.490 |
Why?
|
| United States Public Health Service | 1 | 2014 | 31 | 0.490 |
Why?
|
| Rare Diseases | 1 | 2019 | 553 | 0.490 |
Why?
|
| Information Storage and Retrieval | 2 | 2020 | 824 | 0.490 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 686 | 0.480 |
Why?
|
| Signal Transduction | 32 | 2003 | 23404 | 0.480 |
Why?
|
| Information Systems | 1 | 2016 | 410 | 0.470 |
Why?
|
| Tacrolimus Binding Proteins | 16 | 2002 | 195 | 0.470 |
Why?
|
| Scientific Misconduct | 1 | 2014 | 71 | 0.460 |
Why?
|
| Nuclear Proteins | 9 | 2002 | 5856 | 0.460 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1677 | 0.460 |
Why?
|
| Receptors, CXCR4 | 3 | 2003 | 727 | 0.460 |
Why?
|
| Decision Making | 4 | 2022 | 3888 | 0.450 |
Why?
|
| Gelsolin | 2 | 2006 | 190 | 0.450 |
Why?
|
| Travel | 1 | 2019 | 788 | 0.450 |
Why?
|
| Membrane Microdomains | 2 | 2006 | 203 | 0.440 |
Why?
|
| Phosphotyrosine | 6 | 2006 | 457 | 0.440 |
Why?
|
| Publishing | 2 | 2017 | 833 | 0.440 |
Why?
|
| Language | 2 | 2021 | 1471 | 0.430 |
Why?
|
| Carrier Proteins | 18 | 2003 | 5023 | 0.430 |
Why?
|
| Antigens, Differentiation | 9 | 1999 | 927 | 0.430 |
Why?
|
| Heat-Shock Proteins | 11 | 1996 | 822 | 0.430 |
Why?
|
| Leadership | 1 | 2022 | 1357 | 0.420 |
Why?
|
| Cyclic AMP | 6 | 2002 | 1472 | 0.420 |
Why?
|
| Patient Advocacy | 1 | 2014 | 353 | 0.410 |
Why?
|
| Data Collection | 1 | 2021 | 3339 | 0.410 |
Why?
|
| Tetradecanoylphorbol Acetate | 10 | 2003 | 821 | 0.400 |
Why?
|
| Hybridomas | 15 | 2002 | 452 | 0.390 |
Why?
|
| Organizational Innovation | 1 | 2014 | 559 | 0.390 |
Why?
|
| Advisory Committees | 2 | 2017 | 775 | 0.380 |
Why?
|
| Conflict of Interest | 2 | 2015 | 544 | 0.380 |
Why?
|
| Curriculum | 2 | 2022 | 3605 | 0.380 |
Why?
|
| Communication | 2 | 2022 | 3750 | 0.380 |
Why?
|
| Research Support as Topic | 3 | 2021 | 705 | 0.370 |
Why?
|
| Trust | 1 | 2014 | 505 | 0.350 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2000 | 1085 | 0.350 |
Why?
|
| Nurse Clinicians | 1 | 2009 | 31 | 0.350 |
Why?
|
| Bone Marrow Transplantation | 13 | 2005 | 2765 | 0.330 |
Why?
|
| DNA-Binding Proteins | 15 | 2002 | 9647 | 0.320 |
Why?
|
| Consensus | 3 | 2023 | 2960 | 0.320 |
Why?
|
| Sirolimus | 22 | 2005 | 1565 | 0.310 |
Why?
|
| Protein-Tyrosine Kinases | 9 | 2003 | 2455 | 0.310 |
Why?
|
| Policy | 3 | 2023 | 508 | 0.310 |
Why?
|
| United States | 18 | 2022 | 69872 | 0.310 |
Why?
|
| Program Development | 1 | 2014 | 1316 | 0.300 |
Why?
|
| NFATC Transcription Factors | 8 | 2006 | 381 | 0.300 |
Why?
|
| Computer Security | 2 | 2020 | 262 | 0.300 |
Why?
|
| Cancer Care Facilities | 2 | 2009 | 402 | 0.300 |
Why?
|
| Microtubules | 4 | 2000 | 1089 | 0.280 |
Why?
|
| Cytoskeleton | 4 | 2006 | 1185 | 0.280 |
Why?
|
| Transfection | 15 | 2003 | 5895 | 0.280 |
Why?
|
| Universities | 1 | 2011 | 951 | 0.270 |
Why?
|
| T-Lymphocytes, Cytotoxic | 8 | 1994 | 1821 | 0.270 |
Why?
|
| Risk Management | 1 | 2009 | 571 | 0.260 |
Why?
|
| Financing, Organized | 2 | 2019 | 202 | 0.260 |
Why?
|
| Tyrosine | 6 | 2001 | 1462 | 0.260 |
Why?
|
| Models, Theoretical | 2 | 2014 | 3589 | 0.260 |
Why?
|
| Amino Acid Isomerases | 6 | 1995 | 34 | 0.250 |
Why?
|
| Feasibility Studies | 3 | 2023 | 5077 | 0.240 |
Why?
|
| Calcium | 11 | 2003 | 5755 | 0.240 |
Why?
|
| Educational Status | 2 | 2022 | 2540 | 0.230 |
Why?
|
| Patient Compliance | 1 | 2014 | 2684 | 0.230 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 5035 | 0.230 |
Why?
|
| Cytochalasin D | 1 | 2003 | 92 | 0.230 |
Why?
|
| Transcriptional Activation | 7 | 2006 | 1783 | 0.230 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 1996 | 437 | 0.230 |
Why?
|
| Apoptosis | 5 | 2003 | 9724 | 0.230 |
Why?
|
| Molecular Sequence Data | 22 | 2003 | 18111 | 0.230 |
Why?
|
| Cytoplasm | 7 | 1999 | 1536 | 0.220 |
Why?
|
| Chemokines, C | 1 | 2002 | 9 | 0.220 |
Why?
|
| Up-Regulation | 5 | 2003 | 4222 | 0.220 |
Why?
|
| Biological Specimen Banks | 2 | 2020 | 711 | 0.220 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2003 | 193 | 0.220 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2003 | 1862 | 0.210 |
Why?
|
| Phosphoproteins | 7 | 2001 | 2441 | 0.210 |
Why?
|
| Research Personnel | 4 | 2023 | 573 | 0.210 |
Why?
|
| International Cooperation | 2 | 2020 | 1420 | 0.200 |
Why?
|
| Ligases | 1 | 2003 | 333 | 0.200 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 4 | 2003 | 67 | 0.200 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2001 | 2917 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2003 | 4554 | 0.200 |
Why?
|
| Antigens, CD7 | 1 | 2001 | 21 | 0.200 |
Why?
|
| Protein Kinase C | 6 | 2003 | 1227 | 0.200 |
Why?
|
| Public Opinion | 2 | 2016 | 477 | 0.190 |
Why?
|
| Ethical Relativism | 1 | 2020 | 6 | 0.190 |
Why?
|
| Milk Proteins | 1 | 2001 | 169 | 0.190 |
Why?
|
| Amino Acid Sequence | 17 | 2003 | 13814 | 0.190 |
Why?
|
| Cell Line | 20 | 2003 | 16000 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 28 | 2006 | 9274 | 0.190 |
Why?
|
| Trans-Activators | 3 | 2001 | 2926 | 0.190 |
Why?
|
| Membrane Fusion | 1 | 2002 | 276 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7282 | 0.190 |
Why?
|
| Response Elements | 1 | 2002 | 312 | 0.180 |
Why?
|
| Dentistry | 1 | 2021 | 113 | 0.180 |
Why?
|
| Republic of Korea | 1 | 2022 | 538 | 0.180 |
Why?
|
| Immunoconjugates | 2 | 1999 | 901 | 0.180 |
Why?
|
| Phosphorylation | 11 | 2006 | 8436 | 0.180 |
Why?
|
| Recycling | 1 | 2019 | 17 | 0.180 |
Why?
|
| Blood Cells | 2 | 2017 | 309 | 0.180 |
Why?
|
| United States Dept. of Health and Human Services | 2 | 2017 | 90 | 0.170 |
Why?
|
| Gene Expression Regulation | 8 | 2003 | 12073 | 0.170 |
Why?
|
| Beneficence | 1 | 2019 | 53 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2001 | 647 | 0.170 |
Why?
|
| Animals | 64 | 2005 | 168768 | 0.170 |
Why?
|
| Publication Bias | 1 | 2020 | 162 | 0.170 |
Why?
|
| Cooperative Behavior | 3 | 2017 | 1504 | 0.170 |
Why?
|
| Cloning, Molecular | 7 | 2003 | 4320 | 0.160 |
Why?
|
| Dyneins | 1 | 1999 | 123 | 0.160 |
Why?
|
| Hydroxychloroquine | 1 | 2022 | 412 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2023 | 599 | 0.160 |
Why?
|
| Organizational Case Studies | 1 | 2019 | 299 | 0.160 |
Why?
|
| Depsipeptides | 1 | 1999 | 94 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 1081 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2009 | 2708 | 0.160 |
Why?
|
| Organizational Culture | 2 | 2014 | 510 | 0.160 |
Why?
|
| Enzyme Activation | 8 | 2003 | 3702 | 0.160 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2019 | 108 | 0.160 |
Why?
|
| Chemokines | 1 | 2002 | 970 | 0.160 |
Why?
|
| Health Priorities | 2 | 2021 | 380 | 0.150 |
Why?
|
| Population Dynamics | 1 | 2020 | 302 | 0.150 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 4 | 2003 | 91 | 0.150 |
Why?
|
| Leukapheresis | 1 | 2017 | 131 | 0.150 |
Why?
|
| Gene Expression | 6 | 2006 | 7798 | 0.150 |
Why?
|
| Ribosomal Protein S6 Kinases | 6 | 1995 | 205 | 0.150 |
Why?
|
| Hypotension | 1 | 2023 | 884 | 0.150 |
Why?
|
| Personal Autonomy | 1 | 2019 | 298 | 0.140 |
Why?
|
| Chromosomes | 1 | 2000 | 596 | 0.140 |
Why?
|
| Kinetics | 9 | 2002 | 6476 | 0.140 |
Why?
|
| Protein Kinases | 3 | 1992 | 1640 | 0.140 |
Why?
|
| Plant Proteins | 1 | 1999 | 364 | 0.140 |
Why?
|
| Cell Polarity | 1 | 2000 | 645 | 0.140 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 1998 | 224 | 0.140 |
Why?
|
| Cytoskeletal Proteins | 2 | 2000 | 1364 | 0.140 |
Why?
|
| Recombinant Proteins | 12 | 2000 | 6621 | 0.140 |
Why?
|
| Research Report | 1 | 2020 | 355 | 0.140 |
Why?
|
| Sialoglycoproteins | 5 | 2002 | 318 | 0.140 |
Why?
|
| Cricetinae | 5 | 1999 | 2475 | 0.140 |
Why?
|
| China | 1 | 2022 | 2245 | 0.140 |
Why?
|
| Serum | 1 | 2017 | 214 | 0.140 |
Why?
|
| Bucladesine | 3 | 2002 | 121 | 0.140 |
Why?
|
| Interleukin-3 | 2 | 1994 | 444 | 0.130 |
Why?
|
| Child | 5 | 2023 | 77709 | 0.130 |
Why?
|
| Causality | 1 | 2022 | 1275 | 0.130 |
Why?
|
| Body Fluids | 1 | 2017 | 319 | 0.130 |
Why?
|
| Oral Health | 1 | 2021 | 474 | 0.130 |
Why?
|
| Cell Communication | 4 | 1993 | 1621 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 11 | 1999 | 6313 | 0.130 |
Why?
|
| Gift Giving | 1 | 2015 | 80 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 3 | 2003 | 116 | 0.130 |
Why?
|
| Moral Obligations | 1 | 2016 | 96 | 0.130 |
Why?
|
| Peptidylprolyl Isomerase | 6 | 1995 | 105 | 0.130 |
Why?
|
| Graft vs Host Disease | 10 | 2005 | 2958 | 0.130 |
Why?
|
| CHO Cells | 4 | 1999 | 1409 | 0.130 |
Why?
|
| Cytokines | 8 | 2000 | 7323 | 0.130 |
Why?
|
| Eye Proteins | 1 | 1998 | 645 | 0.120 |
Why?
|
| Capacity Building | 1 | 2017 | 248 | 0.120 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 1405 | 0.120 |
Why?
|
| Base Sequence | 11 | 2001 | 12797 | 0.120 |
Why?
|
| HIV-1 | 2 | 2002 | 6939 | 0.120 |
Why?
|
| Organizational Policy | 1 | 2017 | 429 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 3707 | 0.120 |
Why?
|
| Social Control, Formal | 1 | 2014 | 110 | 0.120 |
Why?
|
| Mice | 38 | 2005 | 81201 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2023 | 2682 | 0.120 |
Why?
|
| Plasma | 1 | 2017 | 575 | 0.120 |
Why?
|
| Safety | 3 | 2009 | 1186 | 0.120 |
Why?
|
| Health Care Sector | 1 | 2015 | 194 | 0.120 |
Why?
|
| Blood Proteins | 1 | 1998 | 1124 | 0.110 |
Why?
|
| Transcription Factors | 8 | 2002 | 12207 | 0.110 |
Why?
|
| Mast Cells | 3 | 1995 | 1544 | 0.110 |
Why?
|
| Protein Binding | 7 | 2003 | 9384 | 0.110 |
Why?
|
| Lymphoma, T-Cell | 1 | 1995 | 299 | 0.110 |
Why?
|
| RNA, Messenger | 12 | 2003 | 13035 | 0.110 |
Why?
|
| Specimen Handling | 1 | 2017 | 694 | 0.110 |
Why?
|
| Public Health | 3 | 2023 | 2602 | 0.110 |
Why?
|
| Reward | 1 | 2019 | 940 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2001 | 1903 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3135 | 0.100 |
Why?
|
| Cell Degranulation | 1 | 1993 | 287 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2021 | 8319 | 0.100 |
Why?
|
| Receptors, Leukocyte-Adhesion | 2 | 1991 | 53 | 0.100 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 8 | 1991 | 379 | 0.100 |
Why?
|
| Policy Making | 1 | 2016 | 554 | 0.100 |
Why?
|
| Antibody Affinity | 1 | 1992 | 254 | 0.100 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 214 | 0.100 |
Why?
|
| Detergents | 2 | 2006 | 230 | 0.100 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 2003 | 1801 | 0.100 |
Why?
|
| Transplantation Immunology | 1 | 1993 | 546 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-vav | 2 | 2003 | 95 | 0.100 |
Why?
|
| Plasmids | 3 | 1993 | 2308 | 0.100 |
Why?
|
| Equipment and Supplies | 1 | 2014 | 281 | 0.100 |
Why?
|
| Public Policy | 1 | 2016 | 572 | 0.100 |
Why?
|
| Precipitin Tests | 3 | 1999 | 829 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2003 | 10943 | 0.100 |
Why?
|
| Enzyme Precursors | 2 | 2001 | 176 | 0.100 |
Why?
|
| Dihydropyridines | 1 | 1990 | 67 | 0.100 |
Why?
|
| Drug Resistance | 3 | 1995 | 1608 | 0.100 |
Why?
|
| Cell Line, Transformed | 4 | 2002 | 898 | 0.100 |
Why?
|
| Glycoproteins | 1 | 1999 | 2266 | 0.100 |
Why?
|
| Protein Processing, Post-Translational | 2 | 1998 | 1988 | 0.100 |
Why?
|
| Income | 1 | 2020 | 1913 | 0.090 |
Why?
|
| Psychiatry | 1 | 2023 | 1695 | 0.090 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 5321 | 0.090 |
Why?
|
| Pyrans | 1 | 1990 | 54 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 5 | 1993 | 7182 | 0.090 |
Why?
|
| Protein Structure, Tertiary | 3 | 2003 | 3848 | 0.090 |
Why?
|
| COS Cells | 2 | 2003 | 1161 | 0.090 |
Why?
|
| Protein Folding | 1 | 1994 | 840 | 0.090 |
Why?
|
| Cell Cycle Proteins | 2 | 1999 | 3464 | 0.090 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 2760 | 0.090 |
Why?
|
| Cross-Linking Reagents | 3 | 2003 | 694 | 0.090 |
Why?
|
| Cyclohexanols | 1 | 1990 | 127 | 0.090 |
Why?
|
| Erythropoietin | 1 | 1994 | 726 | 0.090 |
Why?
|
| Drug Industry | 1 | 2016 | 746 | 0.090 |
Why?
|
| Iron Chelating Agents | 1 | 1990 | 139 | 0.090 |
Why?
|
| Family | 2 | 2019 | 3147 | 0.090 |
Why?
|
| Immunity, Cellular | 2 | 1993 | 1607 | 0.090 |
Why?
|
| Medical Errors | 2 | 2009 | 1297 | 0.090 |
Why?
|
| Cell Division | 5 | 2000 | 4569 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 3 | 1998 | 1837 | 0.090 |
Why?
|
| Tubulin | 1 | 1993 | 695 | 0.090 |
Why?
|
| Cells, Cultured | 9 | 2003 | 19233 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2003 | 2050 | 0.080 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2000 | 188 | 0.080 |
Why?
|
| Anemia, Aplastic | 3 | 2001 | 226 | 0.080 |
Why?
|
| Faculty, Medical | 1 | 2017 | 1181 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2023 | 3079 | 0.080 |
Why?
|
| Health Services | 1 | 2014 | 758 | 0.080 |
Why?
|
| Research | 1 | 2017 | 1999 | 0.080 |
Why?
|
| Immune Tolerance | 2 | 1994 | 2259 | 0.080 |
Why?
|
| Nursing Staff | 1 | 2009 | 129 | 0.080 |
Why?
|
| HLA Antigens | 3 | 1989 | 1382 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 1990 | 1369 | 0.080 |
Why?
|
| Blotting, Northern | 3 | 2003 | 1581 | 0.080 |
Why?
|
| Immunoblotting | 4 | 2003 | 1683 | 0.080 |
Why?
|
| src Homology Domains | 2 | 1999 | 364 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2014 | 881 | 0.080 |
Why?
|
| Cell Adhesion | 7 | 1993 | 3144 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 4 | 2003 | 2839 | 0.080 |
Why?
|
| Caregivers | 1 | 2019 | 2095 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 1999 | 2938 | 0.080 |
Why?
|
| Membrane Proteins | 3 | 2003 | 7882 | 0.080 |
Why?
|
| Th2 Cells | 2 | 2005 | 1061 | 0.070 |
Why?
|
| B-Lymphocytes | 4 | 1993 | 4666 | 0.070 |
Why?
|
| Politics | 1 | 2014 | 791 | 0.070 |
Why?
|
| Substrate Specificity | 2 | 2006 | 1802 | 0.070 |
Why?
|
| Genomics | 1 | 2023 | 5717 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 1996 | 5096 | 0.070 |
Why?
|
| Checklist | 1 | 2014 | 833 | 0.070 |
Why?
|
| Thiazolidines | 1 | 2006 | 74 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 3 | 2003 | 5867 | 0.070 |
Why?
|
| Oncology Service, Hospital | 1 | 2007 | 57 | 0.070 |
Why?
|
| Structure-Activity Relationship | 4 | 1995 | 3130 | 0.070 |
Why?
|
| Bone Marrow | 2 | 1994 | 2948 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2017 | 2265 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 4839 | 0.070 |
Why?
|
| Clone Cells | 6 | 2003 | 1692 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2014 | 1584 | 0.070 |
Why?
|
| Macromolecular Substances | 2 | 2002 | 1454 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7785 | 0.070 |
Why?
|
| Major Histocompatibility Complex | 1 | 1989 | 936 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2002 | 3773 | 0.070 |
Why?
|
| Graft vs Tumor Effect | 1 | 2005 | 72 | 0.070 |
Why?
|
| Microscopy, Fluorescence | 2 | 2003 | 2700 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 9955 | 0.070 |
Why?
|
| Lymphokines | 2 | 2002 | 949 | 0.070 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3242 | 0.070 |
Why?
|
| Growth Substances | 2 | 2003 | 784 | 0.060 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1989 | 547 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 480 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 4751 | 0.060 |
Why?
|
| Solubility | 1 | 2006 | 1088 | 0.060 |
Why?
|
| Erythrocytes | 3 | 1990 | 2455 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 489 | 0.060 |
Why?
|
| Cricetulus | 2 | 1998 | 818 | 0.060 |
Why?
|
| DNA Primers | 2 | 2001 | 2891 | 0.060 |
Why?
|
| Risk | 1 | 2017 | 9688 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2007 | 392 | 0.060 |
Why?
|
| Graft Rejection | 3 | 1997 | 4397 | 0.060 |
Why?
|
| Interleukin-4 | 2 | 2005 | 1147 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 1998 | 1723 | 0.060 |
Why?
|
| Female | 19 | 2023 | 380193 | 0.060 |
Why?
|
| Education, Medical | 1 | 2015 | 1722 | 0.060 |
Why?
|
| Maprotiline | 1 | 1983 | 4 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2003 | 3921 | 0.060 |
Why?
|
| Dactinomycin | 1 | 2003 | 318 | 0.060 |
Why?
|
| Telemedicine | 1 | 2021 | 2872 | 0.060 |
Why?
|
| Health Personnel | 1 | 2017 | 3219 | 0.060 |
Why?
|
| Sheep | 3 | 1993 | 1437 | 0.060 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 3 | 1998 | 494 | 0.060 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 2 | 1993 | 67 | 0.060 |
Why?
|
| Physician-Patient Relations | 1 | 2017 | 3229 | 0.060 |
Why?
|
| Thiazoles | 1 | 1990 | 1483 | 0.060 |
Why?
|
| Anthracenes | 1 | 1983 | 84 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2023 | 6598 | 0.060 |
Why?
|
| Leukemia | 6 | 2001 | 1510 | 0.060 |
Why?
|
| Endoplasmic Reticulum | 2 | 2003 | 1146 | 0.060 |
Why?
|
| Molecular Weight | 3 | 1996 | 2255 | 0.060 |
Why?
|
| Pediatrics | 1 | 2018 | 3475 | 0.060 |
Why?
|
| Pseudopodia | 1 | 2003 | 172 | 0.060 |
Why?
|
| Expressed Sequence Tags | 1 | 2003 | 255 | 0.050 |
Why?
|
| Chemokine CCL3 | 1 | 2002 | 84 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 3 | 1995 | 1602 | 0.050 |
Why?
|
| Chemokine CCL4 | 1 | 2002 | 129 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 4 | 1998 | 2505 | 0.050 |
Why?
|
| Macrophage Inflammatory Proteins | 1 | 2002 | 123 | 0.050 |
Why?
|
| Enzyme Inhibitors | 3 | 2000 | 3799 | 0.050 |
Why?
|
| Chromatography, Ion Exchange | 2 | 1992 | 306 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2018 | 4446 | 0.050 |
Why?
|
| Wiskott-Aldrich Syndrome | 3 | 1991 | 131 | 0.050 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2003 | 144 | 0.050 |
Why?
|
| Glycosylation | 2 | 1996 | 1128 | 0.050 |
Why?
|
| Interleukin-16 | 1 | 2001 | 33 | 0.050 |
Why?
|
| Tissue Distribution | 3 | 2003 | 2327 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 3395 | 0.050 |
Why?
|
| Interleukin-1 | 2 | 2000 | 1263 | 0.050 |
Why?
|
| Software | 1 | 2016 | 4441 | 0.050 |
Why?
|
| Depression | 1 | 2021 | 7759 | 0.050 |
Why?
|
| Binding Sites | 3 | 1996 | 6111 | 0.050 |
Why?
|
| Golgi Apparatus | 1 | 2003 | 410 | 0.050 |
Why?
|
| Binding, Competitive | 3 | 1992 | 1157 | 0.050 |
Why?
|
| Giant Cells | 1 | 2002 | 187 | 0.050 |
Why?
|
| Aspartic Acid | 2 | 1995 | 576 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2003 | 411 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2018 | 4468 | 0.050 |
Why?
|
| Chemokine CXCL10 | 1 | 2002 | 305 | 0.050 |
Why?
|
| Losartan | 1 | 2023 | 299 | 0.050 |
Why?
|
| Chloroquine | 1 | 2022 | 279 | 0.050 |
Why?
|
| Frustration | 1 | 2020 | 22 | 0.050 |
Why?
|
| STAT5 Transcription Factor | 1 | 2001 | 259 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2014 | 3531 | 0.050 |
Why?
|
| Epitopes | 2 | 2003 | 2571 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2002 | 422 | 0.050 |
Why?
|
| Cyclosporins | 2 | 1991 | 220 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2001 | 119 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2001 | 2916 | 0.050 |
Why?
|
| Tachycardia | 1 | 1983 | 619 | 0.050 |
Why?
|
| Open Reading Frames | 1 | 2003 | 811 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2022 | 316 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2021 | 23336 | 0.040 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 1999 | 1887 | 0.040 |
Why?
|
| Microtubule Proteins | 1 | 1999 | 61 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 2002 | 690 | 0.040 |
Why?
|
| Cell Compartmentation | 1 | 2000 | 402 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2002 | 514 | 0.040 |
Why?
|
| European Union | 1 | 2020 | 158 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 1992 | 5534 | 0.040 |
Why?
|
| Yeasts | 1 | 2000 | 284 | 0.040 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 749 | 0.040 |
Why?
|
| Ionomycin | 2 | 1996 | 109 | 0.040 |
Why?
|
| Outpatients | 1 | 2007 | 1487 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2021 | 2539 | 0.040 |
Why?
|
| Infant | 2 | 2019 | 35134 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 2000 | 235 | 0.040 |
Why?
|
| Cell Extracts | 1 | 1999 | 138 | 0.040 |
Why?
|
| Nocodazole | 1 | 1998 | 97 | 0.040 |
Why?
|
| Community Health Centers | 1 | 2022 | 430 | 0.040 |
Why?
|
| Phospholipase C gamma | 1 | 1999 | 128 | 0.040 |
Why?
|
| Adipocytes | 2 | 1995 | 1185 | 0.040 |
Why?
|
| Zinc Fingers | 1 | 2001 | 583 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2001 | 473 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2003 | 3130 | 0.040 |
Why?
|
| Quality of Health Care | 2 | 2015 | 4369 | 0.040 |
Why?
|
| Health Communication | 1 | 2021 | 214 | 0.040 |
Why?
|
| Male | 17 | 2022 | 350115 | 0.040 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 1998 | 40 | 0.040 |
Why?
|
| Receptor Aggregation | 2 | 1995 | 80 | 0.040 |
Why?
|
| Type C Phospholipases | 1 | 1999 | 292 | 0.040 |
Why?
|
| Multigene Family | 1 | 2001 | 1102 | 0.040 |
Why?
|
| Mitogens | 1 | 1998 | 232 | 0.040 |
Why?
|
| Sphingosine | 1 | 2000 | 307 | 0.040 |
Why?
|
| Models, Biological | 3 | 2002 | 9584 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2000 | 4424 | 0.040 |
Why?
|
| Coercion | 1 | 2018 | 63 | 0.040 |
Why?
|
| Immunotherapy, Active | 1 | 1998 | 60 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 1999 | 13693 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2002 | 1547 | 0.040 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 1997 | 39 | 0.040 |
Why?
|
| Clofazimine | 1 | 1997 | 33 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2023 | 923 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 1025 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 1998 | 335 | 0.040 |
Why?
|
| Cell Size | 1 | 1999 | 643 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 652 | 0.040 |
Why?
|
| Proline | 1 | 1998 | 458 | 0.040 |
Why?
|
| Peptides, Cyclic | 1 | 1999 | 400 | 0.040 |
Why?
|
| Caspase 3 | 1 | 1999 | 758 | 0.040 |
Why?
|
| Protein Conformation | 2 | 2003 | 4010 | 0.040 |
Why?
|
| DNA Mutational Analysis | 3 | 1990 | 4185 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2007 | 1831 | 0.030 |
Why?
|
| Financing, Government | 1 | 2020 | 468 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2023 | 1516 | 0.030 |
Why?
|
| Flow Cytometry | 3 | 1994 | 5974 | 0.030 |
Why?
|
| Time Factors | 6 | 2019 | 40075 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 903 | 0.030 |
Why?
|
| Exocytosis | 2 | 1995 | 354 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1434 | 0.030 |
Why?
|
| Receptors, Interleukin-1 | 2 | 1994 | 262 | 0.030 |
Why?
|
| Caspases | 1 | 1999 | 928 | 0.030 |
Why?
|
| Threonine | 1 | 1996 | 279 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2000 | 1284 | 0.030 |
Why?
|
| Leukemia, T-Cell | 1 | 1995 | 104 | 0.030 |
Why?
|
| Asparagine | 1 | 1995 | 122 | 0.030 |
Why?
|
| Allosteric Regulation | 1 | 1996 | 408 | 0.030 |
Why?
|
| Liver Failure | 1 | 1997 | 241 | 0.030 |
Why?
|
| Emergencies | 1 | 2021 | 1170 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2307 | 0.030 |
Why?
|
| Fungal Proteins | 1 | 1999 | 912 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 20824 | 0.030 |
Why?
|
| Calmodulin | 1 | 1995 | 209 | 0.030 |
Why?
|
| Thymus Gland | 3 | 1994 | 1267 | 0.030 |
Why?
|
| Rwanda | 1 | 2017 | 703 | 0.030 |
Why?
|
| Viral Vaccines | 1 | 2020 | 636 | 0.030 |
Why?
|
| Leukemia, Myeloid | 1 | 1998 | 707 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2015 | 241 | 0.030 |
Why?
|
| Health Resources | 1 | 2021 | 911 | 0.030 |
Why?
|
| Molecular Mimicry | 1 | 1995 | 201 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2021 | 2715 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 3873 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2019 | 695 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 1085 | 0.030 |
Why?
|
| Membrane Fluidity | 2 | 1995 | 73 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2005 | 6386 | 0.030 |
Why?
|
| Myelodysplastic Syndromes | 4 | 1997 | 1352 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1999 | 1728 | 0.030 |
Why?
|
| Spleen Focus-Forming Viruses | 1 | 1993 | 16 | 0.030 |
Why?
|
| Virus Replication | 1 | 2002 | 2535 | 0.030 |
Why?
|
| beta Catenin | 1 | 1999 | 1059 | 0.030 |
Why?
|
| Th1 Cells | 1 | 1999 | 1057 | 0.030 |
Why?
|
| Friend murine leukemia virus | 1 | 1993 | 65 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 1998 | 2086 | 0.030 |
Why?
|
| Androstadienes | 1 | 1995 | 345 | 0.030 |
Why?
|
| Antigen-Antibody Reactions | 2 | 1995 | 363 | 0.030 |
Why?
|
| Adjuvants, Immunologic | 2 | 1997 | 1000 | 0.030 |
Why?
|
| Rosette Formation | 1 | 1993 | 153 | 0.030 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 427 | 0.030 |
Why?
|
| Lymphocyte Cooperation | 1 | 1993 | 112 | 0.030 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1983 | 2269 | 0.030 |
Why?
|
| Prazosin | 1 | 1992 | 96 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2003 | 3493 | 0.030 |
Why?
|
| Mutation | 2 | 1995 | 29786 | 0.030 |
Why?
|
| Comprehension | 1 | 2018 | 610 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1993 | 878 | 0.030 |
Why?
|
| Azides | 1 | 1992 | 116 | 0.030 |
Why?
|
| Cell Membrane | 4 | 1991 | 3749 | 0.030 |
Why?
|
| Daunorubicin | 1 | 1992 | 158 | 0.030 |
Why?
|
| Forecasting | 1 | 2021 | 2951 | 0.030 |
Why?
|
| Escherichia coli | 2 | 1996 | 4217 | 0.030 |
Why?
|
| Antigen-Antibody Complex | 1 | 1994 | 517 | 0.030 |
Why?
|
| Gentamicins | 1 | 1993 | 255 | 0.030 |
Why?
|
| Lymphoma | 1 | 2001 | 1877 | 0.030 |
Why?
|
| Deamino Arginine Vasopressin | 3 | 1982 | 91 | 0.030 |
Why?
|
| HTLV-I Infections | 1 | 1992 | 101 | 0.030 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1992 | 318 | 0.030 |
Why?
|
| India | 1 | 2018 | 2197 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1993 | 484 | 0.030 |
Why?
|
| Phenotype | 4 | 1992 | 16367 | 0.030 |
Why?
|
| Bone Marrow Purging | 1 | 1991 | 109 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 708 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2000 | 3207 | 0.030 |
Why?
|
| Adult | 15 | 2009 | 214052 | 0.030 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1992 | 191 | 0.020 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 738 | 0.020 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1993 | 433 | 0.020 |
Why?
|
| Point Mutation | 1 | 1996 | 1624 | 0.020 |
Why?
|
| Inositol Phosphates | 1 | 1991 | 180 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2001 | 2850 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1993 | 798 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1992 | 573 | 0.020 |
Why?
|
| Guinea Pigs | 1 | 1993 | 1386 | 0.020 |
Why?
|
| Transcription, Genetic | 2 | 1998 | 7721 | 0.020 |
Why?
|
| Testicular Neoplasms | 1 | 1997 | 806 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2023 | 5388 | 0.020 |
Why?
|
| Deferoxamine | 1 | 1990 | 151 | 0.020 |
Why?
|
| Arginine Vasopressin | 2 | 1980 | 130 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 1998 | 1023 | 0.020 |
Why?
|
| Mitochondria | 1 | 2003 | 3514 | 0.020 |
Why?
|
| Ricin | 1 | 1990 | 72 | 0.020 |
Why?
|
| Feedback | 1 | 2014 | 795 | 0.020 |
Why?
|
| Antibodies | 1 | 1998 | 2460 | 0.020 |
Why?
|
| Solutions | 1 | 1990 | 426 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2213 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 1990 | 219 | 0.020 |
Why?
|
| Integrins | 1 | 1994 | 846 | 0.020 |
Why?
|
| beta-Galactosidase | 1 | 1990 | 574 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 1998 | 1376 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 1992 | 360 | 0.020 |
Why?
|
| Transplantation, Homologous | 4 | 2001 | 4777 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1983 | 6442 | 0.020 |
Why?
|
| Bone Marrow Cells | 3 | 1992 | 2513 | 0.020 |
Why?
|
| Immunotoxins | 1 | 1990 | 179 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 1990 | 562 | 0.020 |
Why?
|
| Pokeweed Mitogens | 1 | 1988 | 38 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 1415 | 0.020 |
Why?
|
| Massachusetts | 1 | 2022 | 8662 | 0.020 |
Why?
|
| Steroids | 1 | 1994 | 930 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 1993 | 973 | 0.020 |
Why?
|
| Ribosomes | 1 | 1992 | 500 | 0.020 |
Why?
|
| Receptors, HIV | 1 | 1989 | 163 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 1995 | 1463 | 0.020 |
Why?
|
| Iodine Radioisotopes | 1 | 1992 | 1032 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 1992 | 541 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 2865 | 0.020 |
Why?
|
| Colony-Stimulating Factors | 1 | 1989 | 221 | 0.020 |
Why?
|
| Lymphocyte Depletion | 3 | 2001 | 608 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1988 | 370 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 3 | 1982 | 1020 | 0.020 |
Why?
|
| Hyponatremia | 2 | 1982 | 298 | 0.020 |
Why?
|
| Drug Synergism | 1 | 1992 | 1794 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 1997 | 11525 | 0.020 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1999 | 2751 | 0.020 |
Why?
|
| Interleukins | 1 | 1993 | 791 | 0.020 |
Why?
|
| Membrane Lipids | 1 | 1989 | 249 | 0.020 |
Why?
|
| Acute Disease | 2 | 1998 | 7147 | 0.020 |
Why?
|
| Tissue Donors | 3 | 2005 | 2241 | 0.020 |
Why?
|
| Thiocyanates | 1 | 1987 | 70 | 0.020 |
Why?
|
| Fluoresceins | 1 | 1987 | 235 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 1997 | 5445 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 1987 | 225 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1997 | 2282 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1993 | 6171 | 0.020 |
Why?
|
| Amino Acids | 1 | 1993 | 1737 | 0.020 |
Why?
|
| Sodium | 3 | 1982 | 1622 | 0.020 |
Why?
|
| Pancreas | 1 | 1993 | 1687 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1997 | 2119 | 0.020 |
Why?
|
| Cell Cycle | 1 | 1994 | 2967 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 2 | 1994 | 1837 | 0.020 |
Why?
|
| Molecular Structure | 1 | 1990 | 1899 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 1986 | 134 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1993 | 1381 | 0.020 |
Why?
|
| Carmustine | 2 | 1997 | 137 | 0.020 |
Why?
|
| Diffusion | 1 | 1987 | 832 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2020 | 3749 | 0.020 |
Why?
|
| Ligands | 2 | 1991 | 3282 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 1989 | 1588 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1995 | 3203 | 0.020 |
Why?
|
| Liposomes | 1 | 1988 | 759 | 0.020 |
Why?
|
| Treatment Outcome | 6 | 2022 | 63107 | 0.020 |
Why?
|
| Parents | 1 | 2018 | 3405 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1989 | 1475 | 0.010 |
Why?
|
| beta-N-Acetylhexosaminidases | 2 | 1995 | 53 | 0.010 |
Why?
|
| Cell Differentiation | 3 | 1995 | 11486 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 1995 | 4805 | 0.010 |
Why?
|
| Etoposide | 2 | 1997 | 641 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1993 | 2073 | 0.010 |
Why?
|
| Cyclophosphamide | 3 | 1997 | 2242 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1988 | 1537 | 0.010 |
Why?
|
| DNA | 3 | 1993 | 7294 | 0.010 |
Why?
|
| Whole-Body Irradiation | 2 | 1998 | 449 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1993 | 3424 | 0.010 |
Why?
|
| Middle Aged | 11 | 2021 | 213390 | 0.010 |
Why?
|
| Chronic Disease | 2 | 1997 | 9145 | 0.010 |
Why?
|
| Hypercalcemia | 1 | 1986 | 409 | 0.010 |
Why?
|
| Genes | 1 | 1987 | 1893 | 0.010 |
Why?
|
| Methotrexate | 2 | 2001 | 1728 | 0.010 |
Why?
|
| Combined Modality Therapy | 4 | 1997 | 8642 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 1989 | 1366 | 0.010 |
Why?
|
| Iron | 1 | 1990 | 1774 | 0.010 |
Why?
|
| Disease-Free Survival | 3 | 1997 | 6896 | 0.010 |
Why?
|
| HIV | 1 | 1989 | 1604 | 0.010 |
Why?
|
| RNA | 1 | 1992 | 2749 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1990 | 2133 | 0.010 |
Why?
|
| Internet | 1 | 2014 | 3056 | 0.010 |
Why?
|
| Quality of Life | 1 | 2022 | 12802 | 0.010 |
Why?
|
| Ganglionic Stimulants | 1 | 2000 | 19 | 0.010 |
Why?
|
| Hydroquinones | 1 | 2000 | 36 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 2000 | 76 | 0.010 |
Why?
|
| Catechols | 1 | 2000 | 61 | 0.010 |
Why?
|
| Cell Survival | 1 | 1991 | 5882 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 25039 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1990 | 3759 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1986 | 985 | 0.010 |
Why?
|
| Perception | 1 | 2007 | 1198 | 0.010 |
Why?
|
| Adolescent | 8 | 2001 | 85779 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1987 | 1917 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 2001 | 741 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2007 | 2453 | 0.010 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1986 | 808 | 0.010 |
Why?
|
| Smoke | 1 | 2000 | 227 | 0.010 |
Why?
|
| Cell Movement | 1 | 1991 | 5218 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2018 | 25628 | 0.010 |
Why?
|
| G1 Phase | 1 | 1999 | 415 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1998 | 365 | 0.010 |
Why?
|
| Neoplasms | 1 | 2007 | 21696 | 0.010 |
Why?
|
| Insulin | 1 | 1992 | 6582 | 0.010 |
Why?
|
| Biological Products | 1 | 1986 | 860 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2007 | 2278 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 1988 | 4561 | 0.010 |
Why?
|
| Mice, Nude | 2 | 1998 | 3689 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 1998 | 595 | 0.010 |
Why?
|
| Hemoglobin, Sickle | 3 | 1982 | 122 | 0.010 |
Why?
|
| Ionophores | 1 | 1996 | 108 | 0.010 |
Why?
|
| Life Tables | 1 | 1996 | 370 | 0.010 |
Why?
|
| HIV Infections | 1 | 2002 | 16715 | 0.010 |
Why?
|
| Survival Analysis | 2 | 2001 | 10252 | 0.010 |
Why?
|
| Biological Availability | 1 | 1996 | 397 | 0.010 |
Why?
|
| Nicotine | 1 | 2000 | 681 | 0.010 |
Why?
|
| Aged | 4 | 2021 | 163288 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1994 | 112 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1998 | 1828 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1996 | 318 | 0.010 |
Why?
|
| Histocompatibility | 1 | 1996 | 330 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1996 | 549 | 0.010 |
Why?
|
| Fibronectins | 1 | 1998 | 726 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 1995 | 286 | 0.010 |
Why?
|
| Centrifugation, Isopycnic | 1 | 1993 | 8 | 0.010 |
Why?
|
| Mice, Inbred CBA | 1 | 1994 | 448 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1995 | 1101 | 0.010 |
Why?
|
| Boston | 1 | 2007 | 9312 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 803 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 4933 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1997 | 498 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1986 | 2249 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 1994 | 297 | 0.010 |
Why?
|
| Parity | 1 | 1996 | 929 | 0.010 |
Why?
|
| Antioxidants | 1 | 2000 | 1659 | 0.010 |
Why?
|
| Cytoplasmic Granules | 1 | 1995 | 610 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2001 | 1856 | 0.010 |
Why?
|
| Ribosomal Protein S6 | 1 | 1992 | 70 | 0.010 |
Why?
|
| Genes, myc | 1 | 1993 | 399 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 1995 | 2256 | 0.010 |
Why?
|
| Survival Rate | 2 | 1997 | 12788 | 0.010 |
Why?
|
| Introns | 1 | 1993 | 992 | 0.010 |
Why?
|
| Receptors, IgE | 1 | 1992 | 389 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 1992 | 431 | 0.010 |
Why?
|
| Erythrocytes, Abnormal | 2 | 1982 | 125 | 0.010 |
Why?
|
| Erythrocyte Indices | 2 | 1982 | 146 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 1599 | 0.010 |
Why?
|
| Lymphocytes | 2 | 1989 | 2617 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1991 | 645 | 0.010 |
Why?
|
| Cattle | 1 | 1996 | 3922 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 1994 | 1880 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1993 | 1264 | 0.010 |
Why?
|
| Child, Preschool | 3 | 2001 | 41005 | 0.010 |
Why?
|
| Recurrence | 2 | 1997 | 8340 | 0.010 |
Why?
|
| Cell Separation | 1 | 1994 | 1751 | 0.010 |
Why?
|
| Dogs | 1 | 1993 | 3912 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1990 | 647 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1993 | 2124 | 0.000 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1991 | 524 | 0.000 |
Why?
|
| Cytarabine | 1 | 1990 | 692 | 0.000 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1991 | 1159 | 0.000 |
Why?
|
| Exons | 1 | 1993 | 2439 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2005 | 21833 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 2001 | 12025 | 0.000 |
Why?
|
| Prospective Studies | 2 | 2007 | 53290 | 0.000 |
Why?
|
| Glycosides | 1 | 1987 | 107 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1994 | 5181 | 0.000 |
Why?
|
| Antifungal Agents | 1 | 1991 | 729 | 0.000 |
Why?
|
| Prostaglandins E | 1 | 1986 | 172 | 0.000 |
Why?
|
| Gene Deletion | 1 | 1993 | 2751 | 0.000 |
Why?
|
| Indomethacin | 1 | 1986 | 332 | 0.000 |
Why?
|
| Oxygen | 3 | 1982 | 4189 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1996 | 2148 | 0.000 |
Why?
|
| Prognosis | 2 | 1997 | 29060 | 0.000 |
Why?
|
| Culture Media | 1 | 1986 | 909 | 0.000 |
Why?
|
| Calcitonin | 1 | 1986 | 336 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1997 | 12244 | 0.000 |
Why?
|
| Dinoprostone | 1 | 1986 | 601 | 0.000 |
Why?
|
| Biological Assay | 1 | 1986 | 652 | 0.000 |
Why?
|
| Bone Resorption | 1 | 1986 | 723 | 0.000 |
Why?
|
| Models, Molecular | 1 | 1991 | 5451 | 0.000 |
Why?
|
| Graft Survival | 1 | 1991 | 3737 | 0.000 |
Why?
|
| Water-Electrolyte Balance | 1 | 1982 | 346 | 0.000 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1982 | 287 | 0.000 |
Why?
|
| Immunohistochemistry | 1 | 1993 | 11366 | 0.000 |
Why?
|
| Parathyroid Hormone | 1 | 1986 | 1800 | 0.000 |
Why?
|
| Incidence | 1 | 1996 | 20952 | 0.000 |
Why?
|
| Monocytes | 1 | 1987 | 2596 | 0.000 |
Why?
|
| Risk Factors | 2 | 1997 | 72296 | 0.000 |
Why?
|
| Fluid Therapy | 1 | 1980 | 593 | 0.000 |
Why?
|
| Multiple Myeloma | 1 | 1994 | 5181 | 0.000 |
Why?
|
| Brain | 1 | 1996 | 26388 | 0.000 |
Why?
|